4//SEC Filing
Kewalramani Reshma 4
Accession 0000875320-25-000220
CIK 0000875320other
Filed
Aug 6, 8:00 PM ET
Accepted
Aug 7, 4:23 PM ET
Size
6.6 KB
Accession
0000875320-25-000220
Insider Transaction Report
Form 4
Kewalramani Reshma
DirectorCEO & President
Transactions
- Purchase
Common Stock
2025-08-06$389.08/sh+4,290$1,669,153→ 110,258 total - Purchase
Common Stock
2025-08-06$389.95/sh+5,710$2,226,615→ 115,968 total
Footnotes (3)
- [F1]Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43).
- [F2]Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
- [F3]Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53).
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001735944
Filing Metadata
- Form type
- 4
- Filed
- Aug 6, 8:00 PM ET
- Accepted
- Aug 7, 4:23 PM ET
- Size
- 6.6 KB